Encompass Health Corp SEC Filings

Encompass Health Corp provided forward-looking non-GAAP guidance in an Item 7.01 disclosure, projecting net operating revenue of $5,880 million to $5,980 million, Adjusted EBITDA of $1,220 million to $1,250 million, and adjusted earnings per share from continuing operations of $5.12 to $5.34. The company states it does not provide comprehensive GAAP guidance because certain items cannot be reliably predicted, but it estimates 2025 interest expense and amortization of debt discounts and fees of approximately $125 million and amortization of debt-related items of approximately $10 million. The disclosure is furnished under Regulation FD and is not deemed "filed" for Section 18 purposes.

Encompass Health Corp (EHC) insider Patrick W. Tuer, EVP and Chief Operating Officer, reported a sale of 1,020 shares of Encompass Health common stock on 08/27/2025 at a reported price of $123.59 per share. After the transaction, Mr. Tuer beneficially owned 18,846 shares. The Form 4 was signed by an attorney-in-fact, Patrick Darby, on behalf of the reporting person.

Encompass Health Corporation (EHC) Form 144 reports a proposed sale of 1,020 common shares via UBS Financial Services on the NYSE, with an aggregate market value of $126,061.80. The shares were acquired through restricted stock unit vesting in January–February 2023 (individual lots of 218, 290, 233 and 279 shares) and are scheduled for sale on 08/27/2025. The filer certifies no undisclosed material adverse information and provides no reportable sales in the prior three months.

Douglas E. Coltharp, EVP & Chief Financial Officer of Encompass Health Corporation (EHC), reported multiple non‑derivative transactions on 08/21/2025. The filing shows transfers involving common stock: 27,480 shares were disposed of by the reporting person’s spouse and simultaneously 27,480 shares were acquired by an irrevocable trust in which the reporting person is a beneficiary. After these moves the reporting person reports 37,749 shares beneficially owned via spouse and 125,631 shares indirectly held by an irrevocable trust for the benefit of children; the reporting person disclaims beneficial ownership of the spouse‑held shares. The report was signed by an attorney‑in‑fact.

Encompass Health Corporation (EHC) Q2 2025 condensed summary

Net operating revenues for the three months ended June 30, 2025 were $1,457.7 million (up 12.0% vs. Q2 2024) and $2,913.1 million for the six months ended June 30, 2025 (up 11.3% vs. prior year six months). Net income was $184.9 million for Q2 2025 and net income attributable to Encompass Health was $142.1 million for Q2 2025 vs. $114.1 million in Q2 2024. Diluted EPS for the quarter was $1.39. Adjusted EBITDA was $318.6 million for Q2 2025 and $632.2 million for the six months. Operating cash flow for six months was $558.8 million. Cash, cash equivalents, and restricted cash at June 30, 2025 were $137.4 million.

The company operated 168 inpatient rehabilitation hospitals as of June 30, 2025, completed a May 2025 acquisition of a Fort Myers inpatient rehabilitation unit (51% interest) with $19.0 million goodwill recorded, and continued shareholder distributions via repurchases ($56.8 million YTD) and dividends ($35.1 million YTD). Management estimates certain provisions of the One Big Beautiful Bill Act will produce approximately $180 million of current deductions, yielding an estimated $50 million in cash tax savings in 2025. The filing discloses ongoing Medicare Review Choice Demonstration (RCD) non-affirmations in Alabama cycles and other regulatory risks.